Conference Call and Live Audio Webcast with Slide Presentation Scheduled for August 9, 2018,
4:30 p.m. ET
CORALVILLE, Iowa, July 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical
company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference
call and live audio webcast on Thursday, August 9, 2018, at 4:30 p.m. ET, to discuss its corporate and financial results for the
second quarter 2018.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 5597261
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm
website http://investors.kempharm.com/. An archive of the webcast and presentation will remain available
for 90 days beginning at approximately 5:30 p.m. ET, on August 9, 2018.
About KemPharm:
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious
medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology. KemPharm utilizes
its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD,
pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based
on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD. In addition,
KemPharm has received FDA approval for APADAZ®, an immediate-release combination product candidate of benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. KemPharm is also advancing KP201/IR, an acetaminophen-free immediate-release
formulation of the Company’s benzhydrocodone prodrug candidate. Both APADAZ and KP201/IR are intended for the treatment of acute
pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on
KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.
